Skip to main content

The broad spectrum of healthcare technologies helping to get us out of this pandemic

WHEB Headshots 27
Healthcare technology

On 10 January 2020, the first novel coronavirus genome sequence was made public. This accomplishment effectively fired the starting gun in the race to find a treatment for COVID-19. Three decades ago, it took 13 years to sequence the human genome.1 The latest machines will do it in just over an hour2. Advances in genome sequencing and in other healthcare technologies have played a critical role in controlling the COVID-19 pandemic. The most critical healthcare technologies fall into three broad categories: diagnostics, therapy and vaccination.

Diagnostics – the foundation of an effective treatment strategy

Countries have elected to use different strategies to control infection during the pandemic. Some rely on social distancing and lockdowns, while others count on extensive diagnostics tests. All, however, rely on rapid diagnostics to understand the scale of the pandemic and the speed of transmission. Time is of the essence in the fight against the virus. Rapid diagnostics help interrupt transmission and ensure patients receive effective treatments. Cepheid was one of the first companies to develop a rapid molecular diagnostic test for COVID-19. It is a subsidiary of WHEB investee company Danaher. Work on a new rapid COVID-19 test started in early February 2020. The test received its Emergency Use Authorization just over a month later, on the 21st of March. The test can be used at the point-of-care and delivers a result in under an hour. Previous testing technologies often required more than 24 hours for test results to be confirmed.3

Telehealth has also played a critical role in assisting in the deployment and effective use of diagnostics during the pandemic. Telehealth is the use of communication technology to deliver healthcare services. It enables patients to gain access to health services remotely without exposing themselves to high-risk clinical environments. Demand for telehealth has ballooned since the beginning of the pandemic. In the US, telehealth accounted for 21% of total health ‘visits’ last July compared to less than 0.01% before the pandemic.4 Cerner, a Healthcare IT company in the WHEB strategy, recently launched a new video care platform to address this growing demand for virtual health solutions.

Developing new therapies to treat COVID-19

As a new virus to human beings, there were of course no existing treatments for COVID-19. With the growing scale and severity of the pandemic, researchers did not have time to develop entirely new treatments which typically take years if not decades to come to fruition. Instead, using new artificial intelligence (“AI”) technologies, researchers tried to find existing drugs that could be used to treat the disease. Known as ‘drug repurposing’, this process can also take many years.5 AI was used to dramatically accelerate the process of discovery, screening and validation. Several companies have successfully used AI algorithms to identify drug candidates that can be repurposed for COVID-19.6

Unprecedented pace of vaccine research and development

In addition to developing therapies for treating the disease, huge efforts have been made to develop vaccines that prevent the disease from developing in the first place. While vaccines are not a silver bullet to end the pandemic, they are our best shot to return to some semblance of normality.

The pace at which healthcare businesses have developed and approved COVID-19 vaccines is entirely without precedent. A vaccine has rarely been developed in less than 5 years. We now have several approved vaccines that have been developed and approved in under one year. WHEB’s investee company ICON is a clinical research organisation which conducts trials on behalf of pharmaceutical companies. Since the beginning of the pandemic, the company has supported more than 80 COVID-19 related projects.[7] One of them included the clinical trials of the Pfizer and BioNTech vaccine. It was the first vaccine with positive efficacy results from a phase 3 study and was approved just seven months after the start of clinical trials!8 This extraordinarily rapid process was made possible using innovative approaches and technologies that enabled ICON and their clients to set up testing infrastructure rapidly, recruit patients and conduct monitoring and assessment, often remotely.

Supporting healthier populations

There is an abundance of evidence that pandemics like COVID-19 are becoming increasingly common occurrences. The reasons for this are not expected to change any time soon.9 One way to prevent these pandemics from having such a devastating impact though is to ensure that global populations are healthier. 94% of deaths involving COVID-19 in the US had at least one underlying health condition, according to one study.10 In the UK, 74% of critically ill COVID patients were either overweight or obese.11 Supporting better underlying health in the community is one important way to reduce the death toll of future pandemics. Here too, healthcare technologies can play an important role. The most effective approaches involve prevention and optimal disease management. Both of which can be facilitated by electronic health records (EHRs) and population health management. Cerner is a leading player in both areas. Population health analytics can make use of EHR data to provide more precisely targeted preventative healthcare that ensure patients remain healthy.

One early conclusion that we can draw from the COVID-19 pandemic is the critical importance of advanced healthcare technologies. When the next pandemic happens, as it almost inevitably will, we can be all but certain that they will play an important role again.

1 https://www.nature.com/scitable/topicpage/dna-sequencing-technologies-key-to-the-human-828/
2 https://www.sandiegouniontribune.com/business/biotech/sd-me-illumina-novaseq-20170109-story.html
3 https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30526-9/fulltext
4 https://www.ehrn.org/articles/telehealth-fad-or-the-future/
5 https://www.sciencedirect.com/topics/medicine-and-dentistry/drug-repositioning
6 https://www.futuremedicine.com/doi/full/10.2217/fvl-2020-0130
7 https://www2.iconplc.com/Vaccines_Factsheet
8 https://www.iconplc.com/news-events/press-releases/icon-pfizer-biontech/
9 https://www.gavi.org/vaccineswork/5-reasons-why-pandemics-like-covid-19-are-becoming-more-likely
10 https://www.cdc.gov/mmwr/volumes/69/wr/mm6913e2.htm
11 https://www.worldobesity.org/news/obesity-and-covid-19-policy-statement

Important Notices:
Risks include: the price of shares (“Shares”) in FP WHEB Sustainability Impact Fund, WHEB Sustainable Impact Fund or WHEB Environmental Impact Fund may increase or decrease and you may not get back the amount originally invested, for reasons including adverse market and foreign exchange rate movements. Past performance does not predict future returns. The Fund invests in equities and is exposed to price fluctuations in the equity markets, and focuses on investments in mid-sized companies in certain sectors so its performance may not correlate closely with the MSCI World Index (the benchmark). For full risks, please see fund prospectus on www.whebgroup.com

 

General: This information, its contents and any related communication (altogether, the “Information”) is issued by WHEB Asset Management LLP (“WHEB Asset Management”). It is intended for information purposes only and does not constitute or form part of any offer or invitation to buy or sell any security including any shares in the FP WHEB Sustainability Impact Fund or WHEB Sustainable Impact Fund, including in the United States. It should not be relied upon to make an investment decision in relation to Shares in the FP WHEB Sustainability Impact Fund or WHEB Sustainable Impact Fund or otherwise; any such investment decision should be made only on the basis of the Fund scheme documents and appropriate professional advice. This Information does not constitute advice of any kind, investment research or a research recommendation, is in summary form and is subject to change without notice. The performance shown does not take account of any commissions and costs charged when subscribing to and redeeming shares. WHEB Asset Management has exercised reasonable care in preparing this Information including using reliable sources, however, makes no representation or warranty relating to its accuracy, reliability or completeness or whether any future event may or may not occur. This Information is only made available to recipients who may lawfully receive it in accordance with applicable laws, regulations and rules and binding guidance of regulators. WHEB Asset Management LLP is registered in England and Wales with number OC 341489 and has its registered office at 7 Cavendish Square, London, W1G 0PE. WHEB Asset Management LLP is authorised and regulated by the Financial Conduct Authority with Firm Reference Number 496413.

 

FP WHEB Sustainability Impact Fund

FundRock Partners Limited (formerly Fund Partners Limited) is the Authorised Corporate Director of the Fund and is authorised and regulated by the Financial Conduct Authority with Firm Reference Number 469278 and has its registered office at 6th Floor Bastion House, 140 London Wall, London, EC2Y 5DN. The state of the origin of the Fund is England and Wales. The Representative in Switzerland is ACOLIN Fund Services AG, Leutschenbachstrasse 50, CH-8050 Zurich, whilst the Paying Agent is NPB Neue Privat Bank AG, Limmatquai 1/am Bellevue, P.O. Box, 8024 Zurich . The relevant documents such as the prospectus, the key investor information document (KIIDs), the Articles of Association as well as the annual and semi-annual reports may be obtained free of charge from the Representative in Switzerland.

 

WHEB Sustainable Impact Fund

The Manager of the Fund is FundRock Management Company S.A., authorised and regulated by the Luxembourg regulator to act as UCITS management company and has its registered office at 33, rue de Gasperich, L-5826 Hesperange, Grand-Duchy of Luxembourg. The Representative in Switzerland is ACOLIN Fund Services AG, Leutschenbachstrasse 50, CH-8050 Zurich, whilst the Paying Agent is NPB Neue Privat Bank AG, Limmatquai 1/am Bellevue, P.O. Box, 8024 Zurich. The relevant documents such as the prospectus, the key investor information document (KIIDs), the Articles of Association as well as the annual and semi-annual reports may be obtained free of charge from the representative in Switzerland. The state of the origin of the Fund is Ireland. The Fund is registered for distribution to professional investors in Austria, France, Germany, Italy, Luxembourg, Norway, Singapore, Sweden and the United Kingdom, and is registered for offering to retail investors in Switzerland, Denmark and the Netherlands. The Fund is also available for professional investors in Belgium and Hong Kong. It is not available to investors domiciled in the United States.

 

WHEB Environmental Impact Fund

The Manager of the Fund is FundRock Management Company S.A., authorised and regulated by the Luxembourg regulator to act as UCITS management company and has its registered office at 33, rue de Gasperich, L-5826 Hesperange, Grand-Duchy of Luxembourg. The Fund is registered for distribution to professional investors in the United Kingdom. It is not available to investors domiciled in the United States.

 

The MSCI information may only be used for your internal use, may not be reproduced or re-dissseminated in any form and may not be used as a basis for or a component of any financial instruments or products or indices. None of the MSCI information is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such. Historical data and analysis should not be taken as an indication or guarantee of any future performance analysis, forecast or prediction. The MSCI information is provided on an “as is” basis and the user of this information assumes the entire risk of any use made of this information. MSCI, each of its affiliates and each other person involved in or related to compiling, computing or creating any MSCI information (collectively, the “MSCI Parties”) expressly disclaims all warranties (including, without limitation, any warranties of originality, accuracy, completeness, timeliness, non-infringement, merchantability and fitness for a particular purpose) with respect to this information. Without limiting any of the foregoing, in no event shall any MSCI Party have any liability for any direct, indirect, special, incidental, punitive, consequential (including, without limitation, lost profits) or any other damages (www.msci.com).

Sign up to impact fund updates

Sign up below to receive email updates on our impact investment funds.
{{ errors[0] }}
{{ errors[0] }}
{{ errors[0] }}
{{ errors[0] }}
{{ errors[0] }}
{{ errors[0] }}
Authorised and regulated by the Financial Conduct Authority Copyright 2024© WHEB. All rights reserved Made by Thursday